Change search
Link to record
Permanent link

Direct link
Ardnor, Bjarne
Publications (2 of 2) Show all publications
Öhlund, D., Lundin, C., Ardnor, B., Öman, M., Naredi, P. & Sund, M. (2009). Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. British Journal of Cancer, 101(1), 91-97
Open this publication in new window or tab >>Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer
Show others...
2009 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 101, no 1, p. 91-97Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Pancreas cancer is a dreaded disease with high mortality, despite progress in surgical and oncological treatments in recent years. The field is hampered by a lack of good prognostic and predictive tumour biomarkers to be used during follow-up of patients.

METHODS: The circulating level of type IV collagen was measured by ELISA in pancreas cancer patients and controls. The expression pattern of type IV collagen in normal pancreas, pancreas cancer tissue and in pancreas cancer cell lines was studied by immunofluorescence and Western blot techniques.

RESULTS: Patients with pancreas cancer have significantly increased circulating levels of type IV collagen. In pancreas cancer tissue high levels of type IV collagen expression was found in close proximity to cancer cells in the tumour stroma. Furthermore, pancreas cancer cells were found to produce and secrete type IV collagen in vitro, which in part can explain the high type IV collagen expression observed in pancreas cancer tissue, and the increased circulating levels in pancreas cancer patients. Of clinical importance, our results show that the circulating level of type IV collagen after surgery is strongly related to prognosis in patients treated for pancreas cancer by pancreatico-duodenectomy with curative intent. Persisting high levels of circulating type IV collagen after surgery indicates a quick relapse in disease and poor survival.

CONCLUSION: Our results most importantly show that stroma related substances can be evaluated as potential cancer biomarkers, and thereby underline the importance of the tumour microenvironment also in this context.

extracellular matrix, basement membrane, surgery, circulation, biomarker, pancreas
urn:nbn:se:umu:diva-33778 (URN)10.1038/sj.bjc.6605107 (DOI)19491897 (PubMedID)
Available from: 2010-05-06 Created: 2010-05-06 Last updated: 2018-06-08Bibliographically approved
Öhlund, D., Ardnor, B., Öman, M., Naredi, P. & Sund, M. (2008). Expression pattern and circulating levels of endostatin in patients with pancreas cancer. International Journal of Cancer, 122(12), 2805-2810
Open this publication in new window or tab >>Expression pattern and circulating levels of endostatin in patients with pancreas cancer
Show others...
2008 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 122, no 12, p. 2805-2810Article in journal (Refereed) Published
Abstract [en]

Endostatin is a potent inhibitor of angiogenesis that is cleaved from the basement membrane protein type XVIII collagen. Expression of endostatin has recently been shown by Western blot analysis of tissue lysates in normal pancreas and pancreas cancer tissue. We show here that the expression pattern of type XVIII collagen/endostatin is shifted from a general basement membrane staining and is mainly located in the vasculature during tumor progression. This shift in type XVIII collagen/endostatin expression pattern coincides with an up-regulation of MMPs involved in endostatin processing in the tumor microenvironment, such as MMP-3, MMP-9 and MMP-13. The circulating levels of endostatin was analyzed in patients with pancreas cancer and compared to that of healthy controls, as well as after surgical treatment or in a group of nonoperable patients after intraperitoneal fluorouracil (5-FU) chemotherapy. The results show that patients with pancreas cancer have increased circulating levels of endostatin and that these levels are normalized after surgery or intraperitoneal chemotherapy. These findings indicate that endostatin could be used as a biomarker for pancreas cancer progression.

Blotting; Western, Endostatins/*blood/genetics, Female, Humans, Immunohistochemistry, Male, Matrix Metalloproteinases/metabolism, Pancreatic Neoplasms/*blood/genetics/therapy, Up-Regulation
urn:nbn:se:umu:diva-10601 (URN)10.1002/ijc.23468 (DOI)18360823 (PubMedID)
Available from: 2008-10-08 Created: 2008-10-08 Last updated: 2018-06-09Bibliographically approved

Search in DiVA

Show all publications